scholarly journals Sinomenine hydrochloride sensitizes cervical cancer cells to ionizing radiation by impairing DNA damage response

2018 ◽  
Author(s):  
Dan Zhang ◽  
Yiping Dong ◽  
Ying Zhao ◽  
Congya Zhou ◽  
Yuanjie Qian ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dna Damage ◽  
Ionizing Radiation ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Damage Response ◽  
Cervical Cancer Cells ◽  
Sinomenine Hydrochloride

scholarly journals HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response

2020 ◽  
Vol 1867 (12) ◽  
pp. 118835
Author(s):  
Soumyadip Das ◽  
Arun Pandian Chandrasekaran ◽  
Ki-Sang Jo ◽  
Na Re Ko ◽  
Seung Jun Oh ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Damage Response ◽  
Cervical Cancer Cells

Abstract 2961: Olaparib mediated DNA damage response and its resistant mechanism in cervical cancer cells

2020 ◽  
Author(s):  
Ka Yu Tse ◽  
Stephanie Si Liu ◽  
Horace Hok Yeung Lee ◽  
Philip Pun Ching Ip ◽  
Kin Tak Chan
Keyword(s):  
Cervical Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Damage Response ◽  
Cervical Cancer Cells

scholarly journals LINCS gene expression signatures analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1

2020 ◽  
Author(s):  
Sai Hu ◽  
Pingkun Zhou ◽  
Xiaodan Liu ◽  
Xiaoyao Yin ◽  
Dafei Xie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Dna Damage ◽  
Ionizing Radiation ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Breast Cancer Cells ◽  
Potential Candidate ◽  
Damage Response ◽  
Gene Expression Signatures

AbstractRadioresistance represents the predominant cause for radiotherapy failure and disease progression, resulting in increased breast cancer mortality. Through gene expression signatures analyses of Library of Integrated Network-Based Cellular Signatures (LINCS) and Gene Expression Omnibus (GEO), the present study aimed to identify potential candidate radiosensitizers from known drugs systematically. The similarity of integrated gene expression signatures between irradiated eIF4G1-silenced breast cancer cells and known drugs was measured by enrichment scores. Drugs with positive enrichment scores were selected as potential radiosensitizers. The radiosensitizing effects of the candidate radiosensitizers were analyzed in breast cancer cells (MCF-7, MX-1, and MDA-MB-231) by CCK-8 assays and colony-forming capability after exposure to ionizing radiation. Cell apoptosis was detected by flow cytometry. Expressions of eIF4G1 and a series of DNA damage response proteins were analyzed by Western blot assays. Bosutinib was proposed to be a promising radiosensitizer as its administration markedly reduced the dosages of both the drug and ionizing radiation and was associated with fewer adverse drug reactions. The combined treatment with ionizing radiation and bosutinib significantly increased the cells killing potency in all three cell lines as compared to ionizing radiation or bosutinib alone. MX-1 cells were revealed to be the most sensitive to both ionizing radiation and bosutinib among the three cell lines. Bosutinib noticeably downregulated the expression of eIF4G1 in a dose-dependent manner and also reduced the expression of DNA damage response proteins (including ATM, XRCC4, ATRIP, and GADD45a). Moreover, eIF4G1 could be a key target of bosutinib through which it regulates DNA damage induced by ionizing radiation. Thus, taken together, bosutinib may serve as a potential candidate radiosensitizer for breast cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document